zelpultide alfa

DRUG2 trials

Sponsors

Airway Therapeutics Inc., Airway Therapeutics Spain S.L., Airway Therapeutics, Inc.

Conditions

Bronchopulmonary Dysplasiaprematurity in neonates

Phase 2

Randomized, Double-Blind, Parallel-Group, Adaptive, Three-arm, Phase 2b/3 Multicenter Study to Evaluate the Efficacy and Safety of Zelpultide Alfa in Preventing Bronchopulmonary Dysplasia (BPD) in High-Risk Preterm Neonates Compared to Standard of Care (SOC)

RecruitingCTIS2024-513420-41-00

Airway Therapeutics Inc., Airway Therapeutics Spain S.L.prematurity in neonates

Start: 2025-01-09Target: 135Updated: 2025-12-22

Efficacy and Safety of Zelpultide Alfa in Preterm Neonates at High Risk of Developing Bronchopulmonary Dysplasia (BPD)

RecruitingNCT06897839

Airway Therapeutics, Inc.Bronchopulmonary Dysplasia

Start: 2025-02-03End: 2030-04-30Target: 366Updated: 2026-02-06